Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models

Cancer Research

Volumn 66, Issue 1, 2006, Pages 427-434

  Al Saffar, Nada M S ^a   Troy, Helen ^b   De Molina, Ana Ramírez ^c   Jackson, Laura E ^a   Madhu, Basetti ^b   Griffiths, John R ^b   Leach, Martin O ^a,d   Workman, Paul ^a   Lacal, Juan C ^c   Judson, Ian R ^a   Chung, Yuen Li ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 [4,4' BIS[[4 (DIMETHYLAMINE)PYRIDINIUM 1 YL]METHYL]DIPHENYL]BUTANE DIBROMIDE; ACG20B; ALPHA,ALPHA' BIS(4 PIPERIDINYLPYRIDINIUM 1 YL) PARA XYLENE DIBROMIDE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; BUTANE; CHOLINE; CHOLINE KINASE; CHOLINE KINASE INHIBITOR; ENZYME INHIBITOR; MN58B; ORGANOPHOSPHATE; PARA XYLENE; PHOSPHOLIPID; PHOSPHORUS 31; PHOSPHORYLCHOLINE; PIPERIDINE DERIVATIVE; PROTON; PYRIDINIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; COLON CANCER; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACODYNAMICS; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BUTANES; CARCINOMA; CHOLINE KINASE; COLONIC NEOPLASMS; ENZYME INHIBITORS; HT29 CELLS; HUMANS; MICE; MICE, NUDE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHOSPHORUS; PHOSPHORYLCHOLINE; PROTONS; PYRIDINIUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 31544473808     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1338     Document Type: Article

References (51)

1. Aoyama C, Liao HN, Ishidate K. Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 2004;43:266-81.
2. Exton JH. Signalling through phosphatidylcholine breakdown. J Biol Chem 1990;265:1-4.
3. Kent C. Regulatory and catalytic mechanisms of CTP: phosphocholine cytidylyltransferase. FASEB J 1998;12:58.
4. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995;64:315-43.
5. Chung TW, Huang JS, Mukherjee JJ, Crilly KS, Kiss Z. Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. Cell Signal 2000;12: 279-88.
6. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993; 8:2959-68.
7. Kiss Z, Tomono M. Wortmannin inhibits carcinogen stimulated phosphorylation of ethanolamine and choline. FEBS Lett 1995;358:243-6.
8. Paulson BK, Porter TJ, Kent C. The effect of polycyclic aromatic hydrocarbons on choline kinase activity in mouse hepatoma cells. Biochim Biophys Acta 1989;1004: 274-7.
9. Ramírez de Molina A, Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem Biophys Res Commun 2001;285:873-9.
10. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995;323: 313-22.
11. Ramírez de Molina A, Gutiérrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-22.
12. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002;296:580-3.
13. Hernández-Alcoceba R, Saniger L, Campos J, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-301.
14. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001;4:419-26.
15. Ramírez de Molina A, Rodríguez-González A, Lacal JC. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design. Cancer Lett 2004; 206:137-48.
16. Hernández-Alcoceba R, Fernández F, Lacal JC. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res 1999;59: 3112-8.
17. Ramírez de Molina A, bañez-Coronel M, Gutiérrez R, et al. Choline kinase activation is a critical requirement for the proliferation of primary human epithelial cells and breast tumor progression. Cancer Res 2004;64: 6732-9.
18. Rodríguez-González A, Ramírez de Molina A, Fernández F, et al. Inhibition of choline kinase as specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003;22:8803-12.
19. Rodríguez-González A, Ramírez de Molina A, Fernández F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004;23:8247-59.
20. Gelmon KA, Eisenhauer EA, Harris AL, Ratain MJ, Workman P. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999;91:1281-7.
21. Workman P. Challenges of PK/PD measurements in modern drug development Eur J Cancer 2002;38: 2189-93.
22. Workman P. How much gets there and what does it do?: the need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development Curr Pharm Des 2003;9:891-902.
23. Parulekar WR, Eisenhauer EA. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 2004;96:990-7.
24. Negendank W. Studies of human tumours by MRS: a review. NMR Biomed 1992;5:303-24.
25. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001; 3:36-40.
26. Leach MO, Verrill M, Glaholm J, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized P-31 measurements of response to treatment NMR Biomed 1998;11:314-40.
27. Tarnawski R, Sokol M, Pieniazek P, et al. H-1-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 2002;52:1271-6.
28. McSheehy PMJ. On the role of MRS in drug development NMR Biomed 1999;12:402-3.
29. Al-Saffar NMS, Titley JC, Robertson D, et al. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br J Cancer 2002;86:963-70.
30. Ronen SM, DiStefano F, McCoy CL, et al. Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br J Cancer 1999;80: 1035-41.
31. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996;56:4630-5.
32. Smith TAD, Bush C, Jameson C, et al. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed 1993;6:318-23.
33. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
34. Ting YLT, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 1996; 16:1381-8.
35. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2002;84:691-6.
36. Sharp SY, Kelland LR, Valenti MR, et al. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
37. Chung YL, Troy H, Banerji U, et al. Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J Natl Cancer Inst 2003;95:1624-33.
38. Hotz MA, Gong J, Traganos F, Darzynkiewicz Z. Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 1994;15:237-44.
39. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-Ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer 1998;77:1-10.
40. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous extraction of cellular lipids and water-soluble metabolites: evaluation by NMR spectroscopy. Magn Reson Med 1996;35:194-200.
41. Ordidge RJ, Connelly A, Lohman JAB. Image selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy. J Magn Reson 1986;66:283-94.
42. 31P NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1989;6:92-8.
43. Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med 1990;14:26-30.
44. Madhu B, Troy H, Robinson SP, Howe FA, Stubbs M, Griffiths JR. Site dependence of choline concentration in HT29 tumours studied by in vivo 1H MR spectroscopy [abstract]. Proc Int Soc Magn Reson Med 2003;11:1287.
45. Bergmeyer HU. Methods of enzymatic analysis. Weinheim (Germany): Verlag Chemie; 1974.
46. Workman P, Kaye SB. Translating basic cancer research into new cancer therapeutics. Trends Mol Med 2002;8:51-9.
47. Glunde K, Raman V, Mori N, Mironchik Y, Bhujwalla ZM. Choline kinase knock-down in breast cancer cells using RNA interference is associated with an increase in intracellular lipid droplets and triacylglycerides [abstract]. Proc Int Soc Magn Reson Med 2004;12:2029.
48. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
49. Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J Biol Chem 1994;269: 3858-67.
50. Tercé F, Brun H, Vance DE. Requirement of phosphatidylcholine for normal progression through the cell cycle in C3H/10T1/2 fibroblasts. J Lipid Res 1994;35:2130-42.
51. Walkey CJ, Yu L, Agellon LB, Vance DE. Biochemical and evolutionary significance of phospholipid methylation. J Biol Chem 1998;273:27043-6.